This study investigated fibroblast activation protein (FAP) as a potential biomarker for interstitial lung disease (ILD). Methods like western blot analysis, real-time PCR, immunofluorescence staining, and immunohistochemical staining were used to compare FAP expression in lung tissue samples from ILD patients and controls. Results showed higher FAP protein and mRNA levels in ILD lungs compared to controls. This suggests FAP could be a more precise biomarker for early ILD diagnosis and monitoring treatment response, as opposed to biomarkers previously used. Molecular biology research methods helped verify the data and find this new biomarker.